[ Inside the business ]

STE stock analysis

STE · Steris Plc

Orthopedic, prosthetic and surgical appliances and supplies. Growing 9%. Keeps 19¢ of every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 1.6× sales in 5 yrs. Evidence: sales +9% · 19¢ profit/$1.

01 What's priced in?1.6× sales in 5 yrs
Sales now$6.2B
Needed in 5 yrs$10.0B
Backlog$1.5B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +9%, steady
No customer over 10%
Backlog $1.5B · 0.2× salesPrepaid $62MSales +9%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 19¢ per $1, rising
'22'23'24'25'2619¢
Before running costs: 44% → 44%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.4%/yrDebt $1.9B
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +7%, +7%, then +9% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.8× the market. In the 2022 rate shock it fell 31% while the market fell 24%. Debt is moderate.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

71% Healthcare Segment.

Healthcare Segment 71% · Applied Sterilization Technologies 19% · Life Science 11% (latest quarter)

Where each dollar goes

19¢ profit.

55¢ to make what it sells, 26¢ on research and overhead, 19¢ left over. Revenue $6.2B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, converted paper product manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 156¢ of each $1 of profit.

Competitive advantage

2 of 10 years.

Returns beat its 8.6% cost of capital in 2 of the last 10 years. Gross margin went from 39% to 44%.

Future bets

2% on research.

$119M a year on R&D. $353M on equipment and buildings.

All figures from Steris Plc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.